33 Constipation



10.1055/b-0038-166167

33 Constipation

Rajeev Peravali and David G. Jayne


Abstract


Constipation is an age-old, global problem for which a variety of treatments have been tried. Patients, often young women, may be in distress for days and even weeks before having a bowel movement. The use of a great variety of different laxatives and/or suppositories, with or without the regular use of enemas, has become normal practice for many of these troubled patients. This chapter addresses constipation and its etiology, investigation, diagnosis, and treatment.




33.1 Introduction


Constipation is an age-old and worldwide problem for which a variety of treatments have been tried. In ancient times, the Chinese technique for treating constipation consisted of massaging the abdomen with wooden rollers. Today patients, often young women, may be in distress for days and even weeks before having a bowel movement. The use of a great variety of different laxatives and/or suppositories, with or without the regular use of enemas, has become normal practice for many of these troubled patients.


The perception of what constitutes a normal bowel habit varies widely among populations. The prevalence of constipation in the United Kingdom, defined by Rome II criteria, has been estimated at 8.2%. 1 In another UK survey, 39% of men and 52% of women reported straining at stool on more than one in four occasions. 2 The prevalence of chronic constipation in the United States varies from 2 to 28%. 3 , 4 , 5 , 6 , 7 , 8



33.2 Definition


Constipation is a symptom. The meaning differs between patients and also between different cultures and regions. In a Swedish population study, it was found that a need to take laxatives was the most common manifestation of constipation (57% of respondents). In the same study, women (41%) were twice as likely as men (21%) to regard infrequent bowel motions as representing constipation, whereas equal proportions of men and women regarded hard stools (43%), straining during bowel movements (24%), and pain when passing a motion (23%) as being symptomatic. 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 Due to this ambiguity, an international panel of experts developed the Rome definition. The most current Rome III definition is shown in ▶ Table 33.1.














Table 33.1 Rome III criteria for functional constipation

General criteria




  • Constipation for at least 3 mo during a period of 6 mo



  • Specific criteria apply to at least one out of every four defecations.



  • Insufficient criteria for inflammatory bowel syndrome



  • No stools, or rarely loose stools


Specific criteria (two or more present)




  • Straining



  • Lumpy or hard stools



  • Feeling of incomplete evacuation



  • Sensation of anorectal blockade or obstruction



  • Manual or digital maneuvers applied to facilitate defecation



  • Fewer than three defecations per week


Probert et al 2 compared a validated estimate of the whole gut transit time with self-perceived constipation and the “Rome” definition and found little agreement between the definitions. Of 101 women classified as constipated by one or both of the subjective definitions, 64 had normal transit times. Based on these and other data, the authors questioned the validity of the “Rome” definition and any other definition based on individual’s perceptions, except for infrequency of defecation. Many individuals perceive themselves as constipated, only because they have straining and incomplete evacuation. These symptoms also occur in irritable bowel syndrome. Therefore, it seems reasonable to use stool frequency as a clinical guide. Drossman et al 11 surveyed 789 students and hospital employees and found that 4.2% passed two or fewer stools per week. At present, some use the term constipation exclusively for the description of slow colonic transit, resulting in a stool frequency of fewer than two times per week and reserve the term disturbed or obstructed defecation for all the symptoms associated with impaired evacuation. Devroede 17 believes that a patient should be considered constipated under any of the following circumstances: (1) if the stool weight is less than 35 g/day; (2) if fewer than three stools for women and five for men are passed per week while following a high residue diet (30 g of dietary fiber); or (3) if more than 3 days pass without a bowel movement. Agachan et al 18 developed a constipation scoring system based on the following aspects: stool frequency, evacuation difficulties, abdominal pain, time spent in the lavatory per attempt, assistance required for evacuation, number of unsuccessful attempts per 24 hours, and duration of constipation. This system can be quite useful for both clinical and research purposes.



33.3 Etiology


The causes of constipation are numerous and diverse. Various classifications have been described. 19 , 20 , 21 The classification presented in Box 33.1, although not exhaustive, is fairly comprehensive.



Box 33.1 Classification of Causes of Constipation




  • Mechanical obstruction:




    • Colorectal tumor



    • Diverticulosis



    • Strictures



    • External compression from tumor/other



    • Large rectocele



    • Megacolon



    • Postsurgical abnormalities



    • Anal fissure



  • Neurological disorders/neuropath:




    • Autonomic neuropathy



    • Cerebrovascular disease



    • Cognitive impairment/dementia



    • Depression



    • Multiple sclerosis



    • Parkinson disease



    • Spinal cord pathology



  • Endocrine/metabolic conditions:




    • Chronic kidney disease



    • Dehydration



    • Diabetes mellitus



    • Heavy metal poisoning



    • Hypercalcemia



    • Hypermagnesemia



    • Hyperparathyroidism



    • Hypokalemia



    • Hypomagnesemia



    • Hypothyroidism



    • Multiple endocrine neoplasia II



    • Porphyria



    • Uremia



  • Gastrointestinal disorders and local painful conditions:




    • Irritable bowel syndrome



    • Abscess



    • Anal fissure



    • Fistula



    • Hemorrhoids



    • Levator ani syndrome



    • Megacolon



    • Proctalgia fugax



    • Rectal prolapse



    • Rectocele



    • Volvulus



  • Myopathy:




    • Amyloidosis



    • Dermatomyositis



    • Scleroderma



    • Systemic sclerosis



  • Dietary:




    • Dieting



    • Fluid depletion



    • Low fiber



    • Anorexia, dementia, depression



  • Prescription drugs




    • Antidepressants



    • Antiepileptics



    • Antihistamines



    • Antiparkinson drugs



    • Antipsychotics



    • Antispasmodics



    • Calcium-channel blockers



    • Diuretics



    • Monoamine oxidase inhibitors



    • Opiates



    • Sympathomimetics



    • Tricyclic antidepressants



33.3.1 Diet and Habits


Of outstanding importance are the epidemiologic studies of Burkitt, Painter, Walker, and others, 21 , 22 , 23 which have shown that the fiber content of our foodstuffs is the prime factor that determines the fecal weight or bulk and the rate of transit through the colon. Inadequate dietary fiber, common in the Western diet, produces sparse, inspissated stools, whereas populations with a high fiber diet may have a normal bowel habit of two or three large, soft motions per day. 24 Because peristaltic movements are stimulated by distention of the intestine, they tend to be sluggish when the food bulk is insufficient to cause a normal amount of distention. Excessive ingestion of foods that harden stools, such as processed cheese, and inadequate fluid intake may be contributing factors. Lack of exercise also decreases colonic activity.


Repeatedly ignoring the call to stool results in insensitivity of the reflex initiated by a fecal mass in the rectum. This in turn results in adaptation of the sensory mechanism so that arrival of further propulsive waves fails to produce an adequate call to stool. Ultimately, all natural periodic urges disappear.


There is often a perception by patients that a daily bowel movement is necessary for good health. This belief may lead to the chronic abuse of harsh laxatives. After the bowel has been completely emptied by a purgative, it generally takes 2 days for fecal material to accumulate in sufficient quantity to stimulate the desire for a bowel action. Although this may seem self-evident, the absence of a bowel movement often increases the distress of a patient whose attention is focused on his or her bowel function. Further purgation (because of the failure to have a bowel movement the very next day) will unnecessarily abuse the intestine and ultimately lead to a complete loss of natural bowel habits (cathartic colon).


Environmental circumstances such as unfavorable working conditions, travel, and admission to hospital may cause the patient to ignore the call to stool. Some are obviously only temporary problems.



33.3.2 Structural or Functional Disorders


Constipation may be only one of several symptoms with which a patient with disorders of bowel structure will present. Constipation in association with other symptoms will lead the examining physician to the appropriate diagnosis, often with the aid of certain investigative modalities. Clearly, obstructive lesions explain constipation, but patients with these lesions may have alternating constipation and diarrhea. Similarly, individuals with painful anal lesions suppress the call to stool because of the fear of the pain of defecation. This suppression aggravates the problem because the stool becomes harder and more difficult to pass (a detailed discussion of each cause in this section is provided under the specific heading either later in this chapter or in relevant chapters).


Through the use of radiopaque markers, a slow transit rate—particularly along the transverse, descending, and sigmoid colon—can be demonstrated. Its exact cause is unclear. Patients with idiopathic megabowel have a dilated rectum or distal colon, but ganglion cells are present. Transit studies can also show abnormalities. Patients with irritable bowel syndrome have the dominant complaint of abdominal pain, with constipation only an associated finding in those with constipation-predominant disease. Constipation is not an uncommon symptom associated with diverticular disease and may result from the tendency of the colon to form closed high-pressure segments. Aganglionosis, whether it occurs congenitally in patients with Hirschsprung’s disease or is acquired because of the neurotoxin of Trypanosoma cruzi, will cause constipation.



33.3.3 Neurologic Abnormalities


Defects of innervation such as those that follow pelvic surgery and occur with diseases of the spinal cord and brain are factors contributing to constipation. Severe constipation occurs in all patients who sustain a spinal cord injury. Menardo et al 25 and Levi et al 26 demonstrated that patients with injuries between C4 and T12 have a marked prolongation of transit at the level of the left colon and rectum, with minor degrees of transit delay at the level of the right colon. Several surveys have revealed that constipation in patients with spinal cord injury has a significant impact on their quality of life. 27 , 28



33.3.4 Psychiatric Disorders


Psychiatric disturbances are often associated with constipation. However, the medications used in the treatment of psychiatric illnesses very frequently contribute to or cause constipation in their own right. Some patients may become obsessed with their bowel function or lack thereof and resort to excessive laxative abuse. In addition, certain psychiatric patients will deny bowel actions while, in fact, their bowels are moving. Such patients can be detected with the use of radiopaque markers.



33.3.5 Iatrogenic Causes


A host of medications can contribute to constipation (frequent offenders are listed in Box 33.1). Bedpans are uncomfortable and should be replaced by bedside commodes whenever feasible.



33.3.6 Endocrine and Metabolic Causes


Patients with various endocrine abnormalities with their characteristic clinical patterns may experience constipation. Also included in this group are those patients who are pregnant.



33.4 Investigation



33.4.1 Patient Evaluation


Clinical history and examination is the starting point of evaluation, and in many cases can differentiate slow transit constipation from obstructed defecation, although these subtypes coexist. Attention should be paid to any causative factors and “alarm” symptoms must be excluded.



Red Flags




  • Heme-positive stool



  • Iron-deficiency anemia



  • Patients older than 50 years with no previous colon cancer screening



  • Recent onset of constipation



  • Rectal bleeding



  • Weight loss



33.4.2 History



Stool Frequency

When a patient has two or fewer bowel actions a week, the diagnosis of constipation is considered. The question is whether the reported stool frequency is reliable enough to diagnose constipation. Ashraf et al 28 investigated 45 patients complaining of infrequent defecation with fewer than two bowel actions weekly and found a striking discrepancy between the reported stool frequencies on the one hand and objective measures on the other hand. More than half of the patients who professed constipation were found to have underestimated stool frequency by three or more bowel actions weekly. In this group, a past history of psychiatric problems was common, and bowel symptoms correlated poorly with colonic transit time.



Stool Consistency

This is an indicator of colonic transit and can be classified with the use of a reference chart, such as the Bristol Stool Chart that categorizes stool consistency into seven subtypes (▶ Fig. 33.1).

Fig. 33.1 Bristol Stool Scale. 29 (Adapted with permission from Taylor and Francis; © 1997.)


Symptom Onset

Onset of symptoms is important because onset in childhood may point to a congenital cause such as Hirschsprung’s disease, whereas a more recent onset might point to one of the specific disorders of bowel structure. A recent onset in an adult, especially with blood loss and mucus, is more commonly associated with significant colorectal pathology.



Other Specific Questions

Specific questions about dietary and bowel habits, laxative ingestion, other associated symptoms, and prior abdominal or pelvic surgery may lead to the correct diagnosis. Characteristic symptoms such as prolonged and repeated straining at stool, rectal fullness, sense of incomplete evacuation, and necessity for manual assistance may suggest a defecation disorder.



33.4.3 Physical Examination


In most patients with constipation, abdominal findings will be unremarkable. A stool-filled colon may be palpated. Rarely, a mass suggestive of a carcinoma or hepatomegaly suggestive of metastases may be found.


The anal region should be inspected carefully for findings such as fissures, hemorrhoids, fistulas, and abscesses. Digital examination might reveal a mass suggestive of a rectal neoplasm or a fecaloma. In female patients with a rectocele, the pocket-like defect of the anterior rectal wall can be demonstrated just above the anal sphincter. Almy 30 pointed out that the absence of stool in the rectum suggests that the difficulty lies above the rectum and makes a disorder of defecation unlikely. This observation is not valid if the patient is using laxatives, enemas, or suppositories.


Anal sensitivity and reflexes should be checked. Deficient sensation may represent a neurogenic disorder and cutaneosphincteric reflexes may be absent. In patients with Hirschsprung’s disease, profuse fecal discharge occurs characteristically after rectal examination.



33.4.4 Stool Examination


Gross examination of the stool might reveal a large, hard mass or possibly the pellet-like stools characteristically seen in patients with diverticular disease or irritable bowel syndrome. Stool also should be examined for occult blood, and any positive findings should be investigated further. It has been suggested that determination of stool weight and examination of stool form are mandatory in the evaluation of constipation, because both aspects are closely correlated with colonic transit time, but this is rarely practical within the normal clinic setting. 28 , 31



33.4.5 Biochemical Examination


Routine biochemical examination, including values for electrolytes, calcium, phosphate, urea, creatinine, thyroid stimulating hormone, and free thyroxine, is necessary to exclude those endocrine and metabolic disorders that can cause constipation.


Special biochemical investigations such as of gastrointestinal neuropeptides are of interest, but they are not readily available. Interest has grown in the effect of these neuropeptides on gastrointestinal motility. Using sensitive and specific radioimmunoassays, the concentration of gastrointestinal neuropeptides can be determined quantitatively. 32 The effect of these neuropeptides on the motor activity of the upper gastrointestinal tract (stomach, duodenum, and small intestine) has been established, 32 but the exact role of some of these peptides in the regulation of colonic motor activity has not been determined (▶ Table 33.2).























































Table 33.2 Effect of gastrointestinal neuropeptides on colonic motility

In vivo effect


Gastrointestinal neuropeptides


Stimulation


Gastrin


Motilin


Cholecystokinin


Oxytocin


Corticotropin releasing factor


Neuropeptide Y


Serotonin


Inhibitors


Glucagon


Somatostatin


Secretin


Calcitonin gene-related peptide


Enkephalins


Peptide YY


Unknown


Galanin


Gastrin-releasing polypeptide (VIP)


Neurotensin


Substance P


Bombesin


None


Gastric inhibitory polypeptide


Pancreatic polypeptide


It has been suggested that gastrin and motilin have a stimulating effect on the peristaltic activity of the colon. 32 Patients with constipation have a smaller rise in circulating blood levels of gastrin and motilin after a meal, 33 whereas reduced motilin levels have been reported in pregnancy, when there is a tendency toward constipation. 34 However, it is still unknown whether or not these phenomena are primary or secondary. The pharmacokinetics, catabolism, and release of these hormones are very complex. For example, the release of vasoactive intestinal peptide (VIP) from intramural neurons, especially those neurons in the lamina propria and circular muscle of the gut, is induced by stimulation of preganglionic parasympathetic fibers. 32 This finding demonstrates the complex interaction between hormonal and neurogenic factors. Further investigation is necessary to determine the exact role of gastrointestinal hormones, especially in patients with slow-transit constipation.



33.4.6 Proctosigmoidoscopy


Endoscopic examination is mandatory to rule out the presence of a neoplasm. Nevertheless, in the vast majority of patients complaining of constipation, proctosigmoidoscopic examination will not reveal any abnormality. Frequently, patients with long-standing laxative abuse, mainly involving laxative ingredients of the anthracene family, will demonstrate melanosis coli—a discoloration of the mucosa that may range from light brown to black. In other patients, a solitary rectal ulcer, sometimes associated with anterior mucosal prolapse, will be found.



33.4.7 Luminal Imaging


Although plain films of the abdomen occasionally show the extent of fecal accumulation, the main diagnostic tool to demonstrate structural abnormalities in the colon is colonoscopy, which has the advantage over other modalities in obtaining mucosa imaging and biopsy for histological analysis. Contrast studies, such as barium enema, are largely obsolete and have been surpassed by CT colonography as the preferred radiological imaging technique, although it is generally reserved for patients who are unfit or unable to tolerate colonoscopic examination.



33.4.8 Defecating Proctogram


Defecography or evacuation proctography is an established radiologic technique to image the dynamic changes in rectal anatomy during expulsion of barium paste (▶ Fig. 33.2). This method offers the possibility of visualizing abnormalities such as anterior rectal wall prolapse, rectal intussusception, rectocele, and enterocele. 35 , 36 It also allows measurement of the anorectal angle, which is determined by the tone of the puborectalis and levator ani muscles. The angle becomes more obtuse during attempted evacuation due to relaxation of the pelvic floor. Failure to increase the anorectal angle on straining, sometimes associated with accentuation of the puborectalis impression, is considered a radiologic sign of anismus. In patients with fecal incontinence, the anorectal angle may be widened even at rest (▶ Fig. 33.3). It has been argued, however, that visual assessment of the anorectal angle is rather subjective and, therefore, unreliable. Several authors found wide interobserver and intraobserver variations in the measurement of this angle and concluded that its quantification has only limited clinical value. 37 , 38 Defecography also enables the determination of the position of the pelvic floor by calculating the distance between the anorectal junction and the pubococcygeal line. Demonstrating a drop in the anorectal junction of several centimeters or more below the pubococcygeal line signifies the pathologic descent of the pelvic floor. Evacuation proctography also provides a valid estimate of the rate and degree of rectal emptying. 39 These parameters can also be assessed utilizing scintigraphic methods. 40 The investigation of rectal emptying is considered a major step in the evaluation of constipation, because many patients with infrequent bowel movements also present varying degrees of defecatory impairment. It has been argued, however, that the estimation of time and degree of rectal emptying is rather inaccurate. 41 Furthermore, it is questionable whether a delayed and incomplete evacuation on proctography really represents impaired rectal emptying. Karlbom et al 42 analyzed the relations between proctography findings, rectal emptying, and colonic transit time in 80 constipated patients. The correlation between a sense of obstruction and rectal evacuation as evaluated by defecography was found to be very poor. Patients who claimed emptying difficulties actually had the most efficient evacuation. It has also been suggested that incomplete and prolonged evacuation on proctography may be caused by inability to raise intra-abdominal pressure, thereby simply reflecting inadequate straining. 43 Despite these and other objections, evacuation proctography is still considered as one of the most useful tools in the investigation of patients with constipation and disturbed defecation.

Fig. 33.2 Defecography in a normal patient. (a) At rest, X-ray film and diagram showing a normal anorectal angle of 92 degrees. (b) During straining, X-ray film and diagram showing anorectal angle widens to 137 degrees.
Fig. 33.3 Defecography in an incontinent patient. (a) At rest, loss of anorectal angle and widening of anal canal, pool of barium escaping beyond anal sphincter, and pathologic descent of perineum (anus well below pubococcygeal line) are noted. (b) During straining.


33.4.9 Magnetic Resonance Proctography


More recently, MR proctography has gained popularity as an effective method for evaluating dynamic pelvic floor function (▶ Fig. 33.4). The main advantage over barium proctography is that it does not involve radiation exposure. It makes visualization of the bony landmarks easier and therefore the measurement of anorectal and pelvic floor movements during straining more accurate. Importantly, it allows visualization of the whole pelvis, including the bladder and uterus. It can provide useful information on extrarectal lesions that might cause constipation. It is becoming the investigation of choice in patients with multicompartmental pelvic floor dysfunction.

Fig. 33.4 Defecating MRI demonstrating bladder (b), uterus (u), rectocele (r), and intussusception (i).


33.4.10 Colonic Transit Time


A major step in the evaluation of constipation is the measurement of colonic transit time. The technique can establish an abnormality but also can demonstrate a normal transit time in a patient with a bowel neurosis or in the occasional patient who denies having bowel actions. With the original method described by Hinton et al, 44 20 radiopaque markers of similar specific gravity to feces were ingested on one occasion on the first day before breakfast. Stools were collected and studied with radiography for 7 days or longer until all the pellets had been observed on a radiograph. A variation of this method has been described by Cummings and Wiggins. 45 Markers of different shapes were ingested on three consecutive days. Subsequently, all markers present in a single stool collected on the fourth day were counted. This technique reduces the effect of day-to-day variation in transit time by providing 3-day transit studies from one radiograph. Although these marker-appearance methods do not provide accurate data on transit through the different colonic regions, they can be used as a simple test to assess whole-gut transit time. With the Hinton technique, Evans et al 46 found that 95% of normal male and female individuals pass less than 20% of markers within 12 hours and more than 80% of markers within 120 hours. This finding was similar to the original observation of Hinton et al 44 in male individuals. It has been argued that it is more convenient to measure the disappearance of a marker from the colon rather than its appearance in the stool. Therefore, Martelli et al 47 described a technique whereby the patient ingests a single dose of 20 markers. The progression of the markers is followed by daily films of the abdomen until complete expulsion is noted or for a maximum of 7 days after ingestion of the markers. Normally all the markers have passed within 7 days. The arrival and disappearance of markers in three regions of the colon (right, left, and rectosigmoid) are assessed. For this purpose, the spinal processes and two lines from the fifth lumbar vertebra to the pelvic inlet serve as landmarks (▶ Fig. 33.5). Transit time is considered prolonged when more than 20% of the markers are still present within the colon, 5 days after ingestion. A drawback of interpretation of such studies is that evaluation of transit of contents in any segment is dependent on the amount of markers received from the proximal bowel. To reduce the radiation exposure, Metcalf et al 48 developed a somewhat different technique by giving differently shaped markers on three successive days and taking an abdominal radiograph on the fourth day after ingestion and if necessary on days 7 and 10. Chaussade et al 49 modified this technique by giving identical markers on three consecutive days. The quantification of regional colonic transit with these methods has been validated in healthy individuals. It is questionable, however, whether infrequent radiographs allow correct assessment of the site of delay in constipated patients with irregular mass movements, because the results will be very different if a radiograph is taken just before or just after such an event. It has been suggested that the use of radioisotopes provides more accurate information about regional colonic transit, because multiple images can be obtained with a low radiation dose. An additional advantage of scintigraphy is the clear delineation of the different colonic regions, even in patients with a significant overlap of bowel segments. The use of a radiolabeled meal also yields information about gastric emptying and small bowel transit. 50 The radioisotope can also be administered in a coated capsule, which is designed to dissolve at the pH found in the distal part of the small bowel, 51 or as a liquid through a tube placed to instill it in the cecum or the ascending colon. 52

Fig. 33.5 Landmarks for markers used to determine transit time.

Another technique to measure intestinal transit was developed by Ewe et al. 53 They followed a metal particle on its way through the gastrointestinal tract by means of a portable detector. Basile et al 54 used a magnetized steel sphere and localized this particle with biomagnetic instruments. With this technique they were able to demonstrate that the total colonic transit time in healthy volunteers was 44 ± 5 hours (mean ±SD). Similar figures have been reported by others. The normal values for whole-gut transit time, total colonic transit time, and segmental colonic transit time are listed in ▶ Table 33.3, ▶ Table 33.4, and ▶ Table 33.5.


















































Table 33.3 Normal values for whole-gut transit time, expressed in hours

Authors


No. of subjects


Method


Mean ± SD


Upper limit


Cummings and Wiggins 45


12


Radiopaque markers


54 ± 9


72


Metcalf et al 48


21


Radiopaque markers


53 ± 8


70


Evans et al 46


43


Radiopaque markers


120 ± NS


168


Basile et al 54


12


Magnetic markers


56 ± 5


NS


van der Sijp et al 50


12


Radioisotopes


NS


103


Abbreviations: SD, standard deviation; NS, not stated.
































































































Table 33.4 Normal values for total colonic transit time, expressed in hours

Authors


No. of subjects


Method


Sex


Mean ± SD


Upper limit


Arhan et al 55


38


Radiopaque markers



39 ± 5


93


Metcalf et al 48


73


Radiopaque markers


Male


31 ± 18


66





Female


39 ± 18


75


Chaussade et al 49


22


Radiopaque markers



34 ± 16


67


Meir et al 57


128


Radiopaque markers


Male


30 ± 2


44





Female


41 ± 3


77


Basile et al 54


12


Magnetic markers



44 ± 5


NS


Escalante et al 58


18


Radiopaque markers



28 ± NS


NS


Danquechin Dorval et al 59


82


Radiopaque markers


Male


25 ± NS


77





Female


47 ± NS


91


Bouchoucha et al 60


11


Radiopaque markers



36 ± 3


NS

























































































Table 33.5 Normal values of segmental colonic transit time, expressed in hours

Authors


No. of subjects


Sex


Right colon


Left colon


Rectosigmoid


Arhan et al 55


38



14


14


11


Metcalf et al 48


73


Male


9


9


13




Female


13


14


12


Chaussade et al 56


22



7


9


18


Basile et al 54


12



27


15


12


Escalante et al 58


18



7


10


11


Danquechin Dorval et al 59


82



8


13


12




Male


7


8


8




Female


10


21


17


Bouchoucha et al 60


11



7


16


14


A relatively simple method for assessing colonic transit is using the Sitzmarks (Konsyl Pharmaceuticals, Texas) method. A single Sitzmarks capsule containing 24 radiopaque markers is taken on day 0 by mouth with water and a plain abdominal X-ray is taken on day 5 (▶ Fig. 33.6). The patient is instructed to refrain from laxatives, enemas, or suppositories for 5 days. Patients who expel at least 80% of the markers have grossly normal transit. For patients who have more than 20% of markers remaining a further capsule is given along with a bulking agent and a further X-ray is performed at day 10 to determine the location and extent of the markers. If the markers are scattered throughout the colon, slow transit is suggested. If most of the markers are gathered in the rectosigmoid, a functional outlet obstruction may be present.

Fig. 33.6 Colonic transit study demonstrating numerous retained markers in the right colon on day 5 in keeping with slow transit constipation.


33.4.11 Anorectal Manometry


A number of authors advocate the use of anorectal manometry during the initial evaluation of constipation and disturbed defecation to develop individualized and more effective modes of treatment. 61 , 62


In patients with Hirschsprung’s disease, rectal distention does not induce internal sphincter relaxation. This is referred to as the rectoanal inhibitory reflex (RAIR). Absence of RAIR response to rectal distension is a reliable test in the diagnosis of Hirschsprung’s disease. 63 , 64 Although manometry is clearly useful in discriminating Hirschsprung’s disease from other forms of constipation, its role in the evaluation and management of non-Hirschsprung’s constipation remains unclear. There are few data correlating manometric findings with clinical symptoms and outcome of treatment. Studying encopretic children, Loening-Baucke et al 63 demonstrated that the response to different treatment modalities could be predicted by manometric findings. Borowitz et al 65 studied 44 children with chronic constipation and encopresis. Spasm of the external anal sphincter during attempted defecation was correlated with the patient’s age at onset and duration of symptoms, but manometric findings were not predictive of the ability to defecate. They also questioned the conceptual understanding of childhood constipation, based on the assumption that a diminished sense of rectal distention and paradoxical contraction of the external anal sphincter are the principal causes of constipation and obstructed defecation. In adults, similar conflicting findings have been observed. Pluta et al 66 studied 24 female patients with severe and disabling slow-transit constipation who underwent a subtotal colectomy followed by ileorectal anastomosis. No correlation was noted between the results of the operation and the manometric parameters, except in one case. Patients requiring abnormally high pressures inside a distending rectal balloon for sensory perception and internal anal sphincter relaxation did worse than the others. Another striking predictive factor, noted by these authors, was a history of psychiatric illness.


Many demonstrable pressure abnormalities can be detected by anorectal manometry in patients with idiopathic constipation. The reflex may be normal, the amplitude of relaxation may be less than that in normal controls, or the reflex may be totally absent. The resting pressure of the anal canal may be greater than expected and occasionally is accompanied by a rectoanal inhibitory reflex with an amplitude greater than normal. 67


In several studies, elevated anal resting pressures have been found in patients with idiopathic constipation, but in other studies no pressure abnormalities could be detected. Although some authors suggested a normal amplitude of the internal sphincter reflex, these findings are not supported by the results of two other studies that showed the amplitude of relaxation is less in patients with idiopathic constipation than in normal controls. In patients with severe chronic constipation without megarectum, the threshold for the internal sphincter reflex apparently was normal, whereas in patients with a megarectum the threshold was elevated.


Despite the conflicting published data, manometry should continue as part of the evaluation of the severely constipated patient. Only by the continued study of these patients will there be a resolution of the discrepancies that have been reported to date.


During the last decade, attention has been focused on rectal wall properties. Grotz et al investigated rectal wall contractility in controls and in patients with chronic severe constipation. They found that in patients with constipation, the increase in rectal tone following a meal and after the administration of a cholinergic agonist was significantly blunted. According to these authors, the reduced rectal tone contributes to the inability of these patients to expel stool. 68 Other workers from the Netherlands used an electronic barostat assembly to examine rectal tone in response to an evoked urge to defecate. Under radiological control, an infinitely compliant polyethylene bag was inserted over a guide wire into the proximal part of the rectum. Additionally, a latex balloon was introduced into the distal part of the rectum. This latex balloon was inflated until an urge to defecate was experienced. Simultaneously, rectal wall tone was assessed by measuring the variations in bag volume. These variations were expressed as percentage changes from the baseline volume. Comparing female controls and women with obstructed defecation, a significant difference was found regarding mean distending volume required to elicit an urge to defecate (median values: 125 vs. 320 mL of air). Twenty-four patients (24%) did not feel an urge to defecate at all. In all controls, the evocation of an urge to defecate induced a pronounced increase in rectal tone, proximal to the distending balloon. In symptomatic patients, this increase in rectal tone was significantly lower. Thirty-one patients (31%) showed no increase in rectal tone at all. 69 It has been shown that rectal tone increases after a meal. This phenomenon is absent or blunted in women with obstructed defecation. 70 These data indicate that the sensorimotor function of the rectum is impaired in patients with obstructed defecation. Afferent parasympathetic nerves are thought to mediate rectal filling sensations. These nerves run from the rectum through branches, which are situated on each side of the rectum around the cervix uteri and both lateral vaginal surfaces. This extensive network of nerve fibers can be damaged during hysterectomy and also during rectopexy with division of the lateral ligaments. It is well known that in some women, obstructed defecation starts following pelvic surgery. Varma and Smith studied rectal function in 14 women with intractable constipation following hysterectomy. These patients had significantly decreased rectal sensory perception. 71 It has been shown that constipation occurs more frequently the more radical a hysterectomy is performed. 72 Based on an experimental study in dogs, Shafik et al addressed the important role of the parasympathetic nervous system in the defecation mechanism. 73 These and other data do suggest that a deficit of the afferent parasympathetic nerves contributes to the impaired sensorimotor function of the rectum in women with obstructed defecation.



33.4.12 Electromyography


Electromyography (EMG) can be used as a functional test for the investigation of muscle activity and is a reliable method for the evaluation of electrical activity in the external anal sphincter and puborectalis muscles (Chapter 2). 74


Through electrophysiologic techniques it has been shown that damage can occur to the nerve supply of the external sphincter and the puborectalis muscle in patients with chronic constipation; this damage is probably due to perineal descent during defecation straining. 75 Paradoxical contraction of the pelvic floor during attempted evacuation is considered as the principal cause of functional obstructed defecation, that is, obstructed defecation not associated with a structural abnormality. The terms most frequently used to describe this condition are anismus, spastic pelvic floor syndrome, and nonrelaxing puborectalis syndrome. Despite many limitations, EMG is probably the most specific test providing the best assessment of pelvic floor activity during straining (▶ Fig. 2.29).



33.4.13 Balloon Expulsion Test


The balloon expulsion test is another method commonly used to reach the diagnosis of anismus. This simple test was introduced by Preston and Lennard-Jones in 1985. 76 It has been reported that almost all controls are able to expel a water-filled rectal balloon, whereas many constipated patients fail to do so. Although this observation underscores the difference between controls and patients, it does not signify that the inability to expel a balloon represents anismus. Normal rectal evacuation requires adequate intrarectal pressure, which can be raised by increasing intrapelvic pressure, achieved by voluntary contraction of the diaphragm and abdominal wall muscles. Propulsive contractile activity of the rectal wall is another contributing factor. It has been reported that constipated patients with both prolonged evacuation and pelvic floor descent on proctography are not able to void a small nondeformable rectal balloon because they fail to raise intrarectal pressure. 77 This finding suggests that failure to raise intrapelvic pressure is a major cause of inadequate evacuation.


The aforementioned diagnostic tests are generally recommended, because it is difficult to differentiate subgroups of constipation based on symptoms alone. Despite this recommendation, the clinical utility of these tests is still not known. Recently, Rao et al conducted a systematic review of studies assessing the clinical value of these tests in patients with constipation. Their search revealed no methodologically sound studies, and identified several pitfalls. First, no single test appears to provide a pathophysiological basis for constipation. Often, several tests are required to identify the underlying mechanism. Second, the inclusion criteria for patients with constipation were either not defined or when available there were significant interstudy differences. Third, a reference or gold standard test is still missing. Despite these pitfalls, the authors concluded that, “there is good evidence to support the use of these tests in order to define subtypes of constipation and aid treatment.” 77



33.4.14 Special Examinations



Routine Histologic Examination

In patients with solitary rectal ulcer syndrome, performing a biopsy is mandatory to confirm the diagnosis and exclude an underlying carcinoma. Histologic examination will reveal fibromuscular obliteration of the lamina propria, hypertrophy of the muscularis mucosa, and displacement of glands into the submucosa (▶ Fig. 33.7). 78 , 79

Fig. 33.7 Solitary rectal ulcer syndrome demonstrated by biopsy with thickened lamina propria.

When Hirschsprung’s disease is suspected, a biopsy is indicated because, classically, aganglionosis is diagnostic of Hirschsprung’s disease (▶ Fig. 33.8). There is no consensus as to whether the best biopsy technique is the superficial punch biopsy, deep full-thickness biopsy, or mucosal suction biopsy. Usually biopsy specimens are taken 2 to 3 cm above the dentate line, as recommended by Aldridge and Campbell, 80 , 81 who demonstrated a normal hypoganglionic zone in the region of the internal sphincter. This hypoganglionic zone extends proximally from the dentate line an average of 4 mm in the myenteric plexus, 7 mm in the deep submucous plexus, and 10 mm in the superficial submucous plexus. In two studies, it was suggested that the optimal level at which the biopsy should be taken is 1.0 to 1.5 cm above the dentate line. 81 , 82 The authors chose this lower range because taking rectal biopsy specimens at a higher level may result in a missed diagnosis of ultrashort-segment aganglionosis. 83 It is not certain how the measurements in these reports from pediatric patients might apply to the adult.

Fig. 33.8 Hirschsprung’s disease.

Several difficulties arise in the histopathologic interpretation of biopsy specimens. First, the distal segment of bowel does not contain neurons for up to 25 mm from the distal edge of the internal sphincter, and the normal value for adults is unknown. Second, the severity of the clinical course correlates poorly with the length of the aganglionic segment. A third problem with the histopathologic interpretation lies in the potential existence of “skip” lesions. A fourth problem concerns the qualitative appearance of the nervous plexus. Fifth, although hypoganglionosis causes constipation, the range in the normal number of ganglion cells is not known. 84 Finally, the diagnostic accuracy with routine hematoxylin and eosin staining on superficial biopsies is low, as was demonstrated in a study showing an accuracy of only 61%. 82


Ultrastructural studies of colonic biopsies from patients with a history of long-term laxative abuse, primarily involving anthraquinone derivatives or bisacodyl, indicated that submucosal nerve fibers might be severely damaged. These alterations may correlate morphologically to the clinically evident disturbance of gut motility. 85



Acetylcholinesterase Staining

Increased acetylcholinesterase activity has been demonstrated in patients with Hirschsprung’s disease. 86 , 87 , 88 , 89 With acetylcholinesterase staining, an increased number of enlarged, brown-stained nerve fibers can be found in either the submucosa or the lamina propria (▶ Fig. 33.9). According to Ikawa et al, 82 this technique has many advantages over routine hematoxylin and eosin staining. The authors demonstrated 99% accuracy in the differentiation of patients with Hirschsprung’s disease from patients with idiopathic constipation. Park et al 90 demonstrated a 97% diagnostic accuracy compared with a 74% accuracy of hematoxylin and eosin staining. Routine hematoxylin and eosin staining of superficial biopsy specimens failed to reveal ganglion cells in 39% of their patients without Hirschsprung’s disease, all of whom required repeat superficial biopsy studies or even deep full-thickness biopsies while under general anesthesia. Using acetylcholinesterase staining, this problem can be eliminated. Even if the submucosa is not included in the superficial biopsy, the diagnosis still can be made by studying the lamina propria. The histochemical demonstration of acetylcholinesterase activity in suction rectal biopsy specimens is considered an accurate technique and has been recommended in screening for Hirschsprung’s disease. 91

Fig. 33.9 Acetylcholinesterase staining used to demonstrate parasympathetic nerves. Note axon bundles with dark staining in center of microphotograph, with staining of small filaments in periphery.


Monoclonal Antineurofilament Antibodies

It has been proposed that a distinct visceral neuropathy may be present in patients with idiopathic slow-transit constipation and in patients with idiopathic megacolon. However, with the use of conventional light microscopy (hematoxylin and eosin staining), no abnormalities have been found. Examining resected colon specimens with silver staining (Smith’s method), Preston et al 92 demonstrated complete loss of the argyrophil plexus with a marked increase in Schwann cells, indicating that extrinsic damage to the plexus had occurred. Based on these findings, the authors theorized that the myenteric plexus abnormality is not the primary cause but may be the result of long-standing laxative use. Using conventional light microscopy, Krishnamurthy et al 93 found no apparent abnormalities of the myenteric plexus in 12 patients who underwent subtotal colectomy for constipation. In contrast, silver stains of the myenteric plexus showed quantitatively reduced numbers of argyrophilic neurons in 10 patients, morphologically abnormal argyrophilic neurons in 11, decreased numbers of axons in 11, and increased numbers of variable-size nuclei within ganglia in all 12. Thus, severe idiopathic constipation is associated with a pathologically identifiable abnormality of the myenteric plexus. 93


Koch et al 80 found decreased colonic VIP in patients with idiopathic chronic constipation. This finding could not be confirmed by Tzavella et al, 94 who found normal levels of VIP and decreased levels of the excitatory neurotransmitter substance P in rectal biopsies from patients with slow-transit constipation.


An immunostaining technique using monoclonal antibodies raised against neurofilament (NF2F11; Sanbio) has been described for the investigation of bowel innervation anomalies. 95 In the normally functioning bowel, some axons of the submucous plexus and the myenteric plexus do stain with these monoclonal antibodies (▶ Fig. 33.10a). In contrast to this subtotal (partial) staining in normal bowel, heavy total axon-bundle staining has been found in the aganglionic segment of patients with Hirschsprung’s disease (▶ Fig. 33.10b).

Fig. 33.10 Monoclonal antineurofilament antibody. (a) Normal subtotal staining of axonal fibers in myenteric plexus (arrows). (b) Hirschsprung’s disease, deep stain (increased) in myenteric plexus (arrows). (c) Idiopathic slow-transit constipation: absence of staining in myenteric plexus (arrows).

Schouten et al 96 were able to demonstrate that in 29 out of 39 patients with slow-transit constipation, the apparently normal axon bundles in the myenteric plexus stained markedly less than normal or failed to stain at all with the monoclonal antibody. In 17 patients, this reduced or absent neurofilament expression was found along the entire length of the colon, whereas in 12 patients only a portion of the colon was affected. The same picture was found in the proximal ganglionic segment in 18 of 22 patients with persistent constipation after colectomy for aganglionosis (▶ Fig. 33.10c). 97


Because intrinsic innervation is lacking in patients with Hirschsprung’s disease, the stained axon bundles in the aganglionic segment can only be of extrinsic origin. Therefore, the lack of axonal staining in patients with constipation indicates a disturbed extrinsic innervation. It is unlikely that this is a secondary phenomenon caused by laxatives because the same condition was found in neonates with severe constipation who were never treated with laxatives. Two studies have revealed increased serotonin levels in the colonic mucosa and normal serotonin levels in the colonic muscularis propria of patients with slow-transit constipation. 98 , 99 The question is why colonic motility is reduced and transit is prolonged despite local high and normal serotonin levels. It has been suggested that abnormal expression of the serotonin receptors in the colonic wall contributes to colonic inertia. Recently, Zhao et al were able to demonstrate a reduced expression of serotonin receptors in the left colon of patients with this type of constipation. 100 Wedel et al compared the colonic enteric nervous system of patients with slow-transit constipation with the enteric nervous system of controls. They performed a morphometric analysis of the submucous plexus and the myenteric plexus. This analysis was based on Protein Gene Product 9.5 immunohistochemistry. In patients with slow-transit constipation, the total ganglionic area and neuronal number per intestinal length as well as the mean neuron count per ganglion were significantly decreased within the myenteric plexus and the external part of the submucous plexus. The ratio of glia cells to neurons was increased in myenteric ganglia but not in submucous ganglia. The observed quantitative alterations of the colonic enteric nervous system resemble the histologic features by oligoneuronal hypoganglionosis. 101 Two recent studies provide further evidence for these findings. Bassotti et al examined the surgical specimens from 26 patients with slow-transit constipation. They used conventional and immunohistochemical methods. Comparing patients and controls they found a significant decrease in enteric neurons, glial cells, and interstitial cells of Cajal in the constipated patients. 102 Similar findings have been reported by Lee et al. 103 Although all these data provide evidence for the neuropathologic deficit in patients with slow-transit constipation, it is still not known whether these alterations of the colonic enteric nervous system are secondary to long-standing constipation or represent a primary defect.



33.4.15 Psychological Evaluation


The exact role of psychological factors as related to bowel function has not been defined clearly, but suggestions of such influence have been made. Tucker et al 104 suggested that stool weight and bowel frequency correlated with personality as much as with variations in fiber intake. Heavier stools tended to be produced by individuals who were more socially outgoing, more energetic and optimistic, and less anxious and who described themselves in more favorable terms than others. A common cause of withholding stool during childhood has been attributed to conflict between parent and child over bowel function.


It is well known that constipation and disturbed defecation occur primarily in women. It is still not clear why these conditions are characterized with such preponderance. One explanation might be the relationship between hysterectomy and changes in bowel habits. Another explanation for the female preponderance might be the fact that women are prone to develop a symptomatic rectocele. It is unlikely, however, that the adverse side effects of hysterectomy and the defecation difficulties due to rectoceles account for all the cases of constipation and disturbed defecation. It is well known that many patients use somatization as a defensive strategy for dealing with psychological distress. This unconscious defense mechanism can be uncovered by several psychological tests such as the Minnesota Multiphasic Personality Inventory (MMPI). In 1989, Devroede et al 105 used the MMPI to compare women with idiopathic (functional) constipation and women with arthritis. The authors reported that many constipated women demonstrated a “conversion V” profile pattern, which indicates the presence of a somatization defense structure. This finding has been confirmed by others. 106 In 1990, Drossman et al 107 demonstrated that a history of sexual and physical abuse is a frequent experience in women seen in a referral-based gastrointestinal practice and is particularly common in those with functional gastrointestinal disorders. Of 209 consecutive female patients, 89 (44%) reported a history of abuse, but only 17% had informed their physicians. This extremely high prevalence of a past history of sexual abuse is similar to that found by Leroi et al, 108 who reported that 40% of patients suffering from functional disorders of the lower gastrointestinal tract gave a history of having been victims of sexual abuse in contrast to only 10% of patients with organic disease. The prevalence was similar in private practice and university hospital settings. The most frequent symptom of abused patients was constipation. The prevalence of abuse was four times greater in patients with lower rather than upper functional motor disorders. The risk of having a history of sexual abuse was nine times greater among patients with manometric evidence of anismus. The clinical implications of these findings are noteworthy. Because the vast majority of abused patients do not report their hidden history, this type of information must be actively sought.


Dykes et al 109 performed a psychological enquiry among patients with chronic constipation. These patients were assessed for evidence of previous and current affective disorders. A previous episode of psychiatric illness was noted in 64% of the patients, whereas a current affective disorder was observed in 61% of the subjects. Based on these findings, the authors suggest that patients who present to surgical departments with chronic intractable constipation should routinely have a psychological assessment. It is well known that the vast majority of patients with constipation, especially those with a slow colonic transit, are women. 110 It has been suggested that aspects of female identity provide clues to the underlying nature of this condition. Mason et al conducted a study to examine possible emotional difficulties related to female identity in women with idiopathic constipation and compared the findings with an age-matched group of healthy women and with an age-matched group of women with Crohn’s disease. Women with idiopathic constipation were found to have increased psychological and social morbidity, characterized by anxiety, depression, and social dysfunction. They also had increased somatization, less satisfaction in their sexual life, and an altered perception about female self. 111 It has been shown that this type of morbidity is associated with altered rectal mucosa blood flow, indicating autonomic dysfunction. 112 Chan et al observed defective use of coping strategies in patients with functional constipation. These differing coping mechanisms were reflected in an absent or blunted rectal sensory perception. 113 It has been shown that biofeedback alone is not successful in the treatment of abused patients with anismus. 114 The clinical outcome could be improved by adding psychotherapy to biofeedback conditioning.


Patients with mental illness are liable to the development of megacolon, and constipation may be a presenting symptom of a depressive illness. Patients with anorexia often develop intractable constipation, presumably caused in part by inadequate food intake. A patient may deny the passage of stool, although a transit study may demonstrate clearly that defecation actually has occurred. The denial of passage of stool emphasizes the need to obtain objective evidence of a prolonged transit time before any operative treatment is contemplated.



33.5 Why Treat Constipation?



33.5.1 Dispelling Myths


Patients must be reassured first that there is a wide variation of normality with regard to the frequency of bowel movements. The folklore and mythology associated with the need for daily evacuation must be dispelled. Advertising encourages self-purgation by making people feel guilty about constipation and by portraying daily bowel movements as the secret to a healthy and happy life. Erroneous concepts such as the belief that toxic substances may be absorbed into the body without a daily bowel movement must be cast aside.



33.5.2 Associated Symptoms and Daily Activity


Martelli et al 47 noted that constipation is not without associated symptoms and complications. The authors noted the disappearance of a multitude of symptoms after successful surgical treatment of constipation. Symptoms described included hard stools, stools difficult to evacuate, abdominal distention and bloating, and anorexia. Signs included fecalomas, abdominal masses, and abdominal tenderness. To this list, Thompson 115 added foul breath, furred tongue, flatulence, headache, and irritability. Regardless of the cause of constipation, absence of the numerous associated symptoms should allow the patient to function better in his usual daily activity.



33.5.3 Potential Disease


Although the immediate adverse effect of low-fiber diets may be constipation, the long-term adverse effects may include diverticular disease and malignancy, as noted in studies that link the low-fiber content of the usual Western diet with an increased risk of colon carcinoma and diverticulosis. 22 Three studies suggest the link between carcinoma and constipation. 116 , 117 , 118 More women with carcinoma of the colon had antecedent constipation than a comparable group of controls without constipation. More men with carcinoma of the rectum had a history of constipation. In a study by Wynder and Shigematsu, 118 having three stools per week for a long period of time was considered a risk factor. However, in a penetrating review, Cranston et al 119 examined the evidence linking dietary fiber to gastrointestinal disease. They noted that fiber increases stool weight, decreases whole-gut transit time, and lowers colonic intraluminal pressure. Although fiber may be of benefit in the treatment of constipation, irritable bowel syndrome, and diverticular disease, its role in the prevention or treatment of other gastrointestinal disease has not been established.


The most recent effort to evaluate the association between dietary fiber intake and risk of colorectal carcinoma was reported by Park et al. 120 From 13 prospective cohort studies included in the Pooling Project of Prospective Studies of Diet and Carcinoma, 725,628 men and women were followed up for up to 6 to 20 years across studies. In this large pooled analysis, dietary fiber intake was inversely associated with risk of colorectal carcinoma in age-adjusted analyses. However, after accounting for other dietary risk factors, high dietary fiber intake was not associated with reduced risk of colorectal carcinoma.


No available data substantiate the claim that volvulus of the large bowel is frequently preceded by long-standing constipation. In many cases, hard stools with straining are the initiating factors in the development of fissures and hemorrhoids.



33.5.4 Economic Considerations


Constipation creates an economic problem of staggering proportions. In 2005, purchases of laxatives in ethical and proprietary markets (drugstores and hospitals), excluding other points of sale, totaled an astounding sum of $79,504,000 in Canada and $650,624,300 in the United States (D. Rhodes, personal communication, 2006; IMS Canada Drug Store and Hospital purchases, 2005; IMS America, Drug Store audit and provider perspective). Because these values do not include the consumption of all laxatives, the true figures are undoubtedly much higher. A common misconception is that nonprescription medication is totally safe and without adverse effects. However, if a bowel movement is induced by a laxative, it may be several days before enough stool is present for another bowel movement. Therefore, when an individual attempts to maintain a daily bowel movement with the prolonged use of laxatives, a vicious cycle may develop in which either more of the same laxative or a more potent one must be used. A “cathartic colon” then may develop. Such long-standing use of laxatives creates a varying degree of financial burden on a given patient.



33.6 Diagnosis and Treatment


Careful history and selective investigations will enable the appropriate subclassification of idiopathic chronic constipation. In general, three subgroups are recognized:




  1. Constipation-predominant irritable bowel syndrome (IBS-C). This is constipation without prolongation of transit or disordered evacuatory pelvic floor mechanisms. Often IBS-C is associated with abdominal pain and bloating.



  2. Slow transit constipation. Characterized by prolongation of colonic transit or colonic inertia.



  3. Obstructed defecation. Constipation characterized by normal transit time but an inability to initiate defecation due to a disordered pelvic floor function.


Subdivision, as above, is important to direct therapy, but it needs to be recognized that significant overlap between the subgroups exists. It is known that some patients with slow transit constipation have obstructed defecation and vice versa and all may have an element of abdominal pain and bloating.


Almy 30 described the goals in the treatment of a patient with chronic constipation as follows: restoration of normal frequency and consistency of stools, freedom from the discomforts ordinarily associated with constipation, maintenance of reasonably regular elimination without artificial aids, and relief of any generalized illness of which constipation may be a symptom. Although these goals are the ideal, they should be achieved if at all possible.


Traditionally, the mainstay of treatment has included laxatives, suppositories, and enemas. It is now being recognized that surgery has an increasing role to play in the management of these patients. Therefore, medical treatment is discussed first, followed by consideration of the role of surgery as appropriate for the latter two subgroups described previously.



33.6.1 Medical Treatment



General Recommendations

Specific metabolic and endocrinologic problems such as hypothyroidism must be treated on their own merits. A favorite recommendation is for the patient to sit on the toilet at regular intervals and for prolonged periods, regardless of whether there is an urge to defecate or not. However, the value of such a ritual is open to debate. Antispasmodics may relieve cramping in individuals with irritable bowel syndrome.



Dietary and Lifestyle Changes

Because the most common causes of constipation are faulty diet and habits, management often requires no more than careful examination and reassurance, together with simple guidance. Patients should be advised not to ignore the call to stool because neglect only disrupts the normal adaptive relaxation mechanism of the rectum, yielding fecal stasis. Regular exercise should be encouraged; some patients claim an easier and more satisfactory bowel action with nothing more than a regular walk in the morning or evening. Environmental factors such as working conditions are often difficult to change. Other factors, such as meal patterns (e.g., omission of breakfast), shift work, and dependence on fast foods, may contribute to abnormal bowel function. If the patient’s history reveals excessive ingestion of foods that cause hardened stools, such as processed cheese, such foods might be eliminated or at least reduced in quantity. An adequate daily intake of fluids is encouraged up to 2 to 3 L if need be. Finally, cultural habits and norms may influence an individual’s perception of what is abnormal as opposed to normal function.


Fiber-containing foodstuffs have hydrophilic properties that soften the stool. The increased volume of feces favors the stimulation of a natural peristaltic reflex. Cereals, especially bran, are good agents in this regard. The most inexpensive cereal with the highest concentration of crude fiber is unprocessed bran, or Miller’s bran. 121 This easily obtainable material is effective in lowering intraluminal pressure and decreasing transit time in patients with constipation and diverticular disease. Coarser bran is more beneficial because of its greater water-holding capacity. 122 Of the various fiber components, pectin has the greatest water-holding capacity but produces the smallest change in fecal weight, whereas bran has the lowest water-holding capacity and the largest fecal weight changes. 123 An inverse relationship between water holding and fecal bulking suggests that dietary fiber does not exert its effect on fecal weight simply by retaining water in the gut. There are four ways in which dietary fiber might cause stool bulking. 124 First, the amount of fiber determines the number of bacteria, which are estimated to form 30 to 50% of feces, and there is a direct relationship between stool weight and pentose-containing polysaccharides. Second, water may be absorbed by undigested hydrophilic components of fiber, but the importance of this is questionable. Third, short-chain fatty acids produced by fermentation of dietary fiber accelerate transit and leave less time for the colonic mucosa to reabsorb water. Fourth, stool weight may increase merely because of the increase in undigested residue. In any event, the diet should contain generous portions of vegetables and fruits. Foods with fat (not excessive) are of value. Patients who are unable to achieve adequate intake of fiber-containing foods should supplement their diets with hydrophilic preparations such as psyllium seed extracts, which act in a similar fashion.


In their diet trial, Devroede et al recommended that patients ingest an average of 14.4 g of crude fiber per day. 105 Today the concept of ingesting dietary fiber is generally accepted. Dietary fiber is the residue derived from plant foods that is resistant to human digestive enzymes. 125 The main components of dietary fiber include the structural materials of the plant cell wall (i.e., cellulose, hemicellulose, pectin substances, and lignin) and nonstructural polysaccharides (i.e., gums, mucilages, algal polysaccharides, and modified celluloses). Furthermore, fiber can be considered insoluble or water soluble. The physical and chemical properties of each component of fiber are important in determining the physiologic response to it. For example, the water-insoluble fibers, which include lignin, cellulose, and hemicelluloses, accelerate intestinal transit, augment fecal weight, slow down starch hydrolysis, and delay glucose absorption. Water-soluble fibers, which include pectin and gums, delay intestinal transit, gastric emptying, and glucose absorption and decrease serum cholesterol concentration.


Foods rich in dietary fiber contain a mixture of these fiber components, which are present in the form of a matrix. Food sources of fiber are complex, and the amount of fiber detected varies depending on the plant species and the method used to analyze the fiber content. Crude fiber analysis does not accurately reflect the total amount of dietary fiber in food materials and, in general, underestimates the total amount of fiber in a range from unity to a ratio of 7:1, depending on the specific components of a given food. 126


“How much dietary fiber should the average person consume daily?” is a difficult question to answer. It has been estimated that the average dietary fiber consumed is approximately 19 g/day. For a beneficial effect on stool weight, consumption of 30 to 60 g/day has been suggested, but this estimate would vary from individual to individual. Soluble fiber, which can be readily degraded by bacteria, increases fecal bulk. However, insoluble fiber, which is resistant to bacterial degradation, is responsible for the major contribution to fecal bulk. During a diet trial, patients are instructed to record each bowel movement. They also are instructed to stop taking drugs, if not essential, particularly laxatives, and not to resort to enemas. A diet containing 30 g of dietary fiber from a wide variety of sources is continued for 1 month. Dietary recommendations emphasize the ingestion of sources of insoluble fiber. 127 Sources of fiber and sample diets are shown in ▶ Table 33.6. Patients who fail to respond to a change in diet (e.g., three or more stools per week) may require further studies such as colonic transit time evaluation and manometry. Patients who do respond are encouraged to adopt a high-fiber diet with a generous fluid intake as a daily habit, to prevent constipation.






















































































































































































































Table 33.6 Fiber content of various foods

1 cup (250 mL) cornflakes = 7 g fiber (total) vs. 1 cup (250 mL) raisin bran = 6.7 g fiber (total)


1 slice white bread = 6 g fiber (total) vs. 1 slice whole wheat


bread = 2.0 g fiber (total)


1 cup (250 mL) shredded lettuce = 0.9 g fiber (total) vs. 1 cup coleslaw = 1.9 g fiber (total)


1 chocolate chip cookie = 0.4 g fiber (total) vs. 1 date square = 2.1 g fiber (total)



Dietary fiber (g)



Total


Insoluble


High-fiber breakfast cereals and breads




Fiber, 1.5 cup (125 mL—refer to label)


14.0



All Bran, 0.5 cup (125 mL)


11.8


10.2


Grape Nuts, 0.5 cup (125 mL)


6.0


4.8


Harvest Crunch (raisin-almond), 0.5 cup (125 mL)


3.1


2.1


Muffets 2


4.9


4.2


Fruit and Fiber (date raisin nut), 0.5 cup (125 mL)


4.2



Shredded wheat (spoon size), 0.5 cup (125 mL)


3.2


2.6


Shredded wheat (1 biscuit)


3.0


2.5


Multigrain bagel (large—refer to label)


7.0



Whole wheat bread (1 slice)


2.0



Bran muffin (commercial mix)


1.5



High-fiber fruit




Pear, 1 fresh (170 g)


5.1


3.4


Prunes (cooked), 0.5 cup (125 mL)


4.8



Orange, 1 (150 g)


4.4



Mango, 1 fresh


4.1


2.2


Raspberries (raw), 0.5 cup (125 mL)


3.2


1.0


Raisins, 0.5 cup (125 mL)


3.1


2.0


Apple, 1 with skin (138 g)


2.6



Fig, 1 dried


2.3



Blueberries (raw), 0.5 cup (125 mL)


2.0


1.5


Banana, 1 medium


2.0


1.1


Strawberries (raw), 0.5 cup (125 mL)


1.7


1.0


Peaches canned slices, 0.5 cup (125 mL)


1.7


0.6


Applesauce, 0.5 cup (125 mL)


1.5


1.0


High-fiber snacks




Peanuts, 0.5 cup (125 mL)


5.6


2.8


Nuts, mixed, no peanuts, 0.5 cup (125 mL)


4.2



Popcorn, 1 cup


1.4



High-fiber vegetables




Beans, red kidney, 0.5 cup (125 mL)


6.1


3.3


Peas, green, fresh (cooked), 0.5 cup (125 mL)


5.6


4.2


Corn, fresh, 1 cob (120 g)


4.5



Lentils (cooked), 0.5 cup (125 mL)


4.4


4.2


Chick peas (cooked), 0.5 cup (125 mL)


4.0


3.0


Lima beans (cooked), 0.5 cup (125 mL)


4.0



Cabbage, red (shredded raw), 1 cup (250 mL)


3.8



Potato baked with skin


3.4


1.1


Corn, fresh, niblets (cooked), 0.5 cup (125 mL)


3.2



Sweet potato (mashed cooked), 0.5 cup (125 mL)


3.1


1.9


Brussels sprouts, fresh (cooked), 0.5 cup (125 mL)


3.0


1.6


Carrots, fresh (cooked), 0.5 cup (125 mL)


2.2


1.0


Turnip (cooked), 0.5 cup (125 mL)


2.4



Broccoli, fresh (cooked), 0.5 cup (125 mL)


2.4


1.5


Squash, winter (cooked), 0.5 cup (125 mL)


1.9


1.3


Tomato, 1 medium


1.5


1.0


Celery (chopped raw), 0.5 cup (125 mL)


1.0


0.6


Lettuce (chopped), 1 cup (250 mL)


0.9


0.5



Laxatives

Laxatives are compounds that facilitate the passage and elimination of feces from the colon and rectum. In addition to the treatment of constipation, valid indications for the use of laxatives include preparation for gastrointestinal investigations and surgery.


With the almost countless number of laxatives available on the market today, classification of such drugs becomes extremely important but correspondingly difficult. More than 700 proprietary laxative preparations are available in almost every dosage form. The most meaningful method is based on the mechanism of action of the drug. The classification shown in ▶ Table 33.7 is a modification of the ones presented by Brunton 128 and Curry. 129 The use of all cathartics is contraindicated in a patient with abdominal cramps, colic, nausea, vomiting, or any undiagnosed abdominal pain. Because the drugs in each group act similarly, they are described in groups.





























































Table 33.7 Modified classification of laxatives based on Brunton 128 and Curry 129

Stimulants


Mechanical cleansers


Miscellaneous


Anthracene (emodin, anthraquinone)


Saline laxative


Lactulose




  • Cascara sagrada




  • Magnesium sulfate (Epsom salt, Milk of Magnesia, magnesium citrate, magnesium cardonate, sodium sulfate [Glauber’s salt], sodium phosphate, potassium sodium tartrate [Rochelle salt])


Obsolete cathartics


Calomel, aloe, podophyllum, jalap, colocynth, elaterin, ipomea, gambage, croton oil, sulfur




  • Senna (Senokot)


Bulk forming agents





  • Danthron




  • Psyllium seed preparations (plantago), Metamucil, Konsyl, LA formula, Hydrocil, Mucilose, Sibliny





  • Rhubarb




  • Synthetic mucilloids (methylcellulose, sodium carboxymethyl cellulose)



Castor oil




  • Agar



Diphenylmethane cathartics




  • Tragacanth





  • Bisacodyl (Dulcolax)


Mineral oil





  • Phenolphthalein


Surface-active agents





  • Oxyphensatin acetate




  • Dioctyl sodium sulfosuccinate (Colace, Doxinate, Bulax, DOSS)






  • Poloxalkol






  • Dioctyl calcium sulfosuccinate (Surfak)




Stimulants

Drugs in this group chemically stimulate the intestinal wall to increased peristaltic activity and hence cause gripping, intestinal cramps, increased mucous secretion, and excessively rapid evacuation in some patients. The mechanism of action is by irritation of the intestinal mucosa or by selective action on the enteric nervous system or intestinal smooth muscle. Increased water and electrolyte excretion is attributed to more rapid transit of feces through the intestine. The initiation of the irritant activity may occur in either the small intestine or the large bowel. Although it might be expected that the colon always must be the site of laxative irritant activity, this is not the case. Any agent that increases the propulsive activity of the small intestine necessarily accelerates large bowel peristalsis. These agents are useful in the treatment of acute constipation as well as constipation caused by prolonged bed rest or hospitalization and preparation for radiologic examinations. Abuse, however, may lead to cathartic colon, that is, a poorly functioning large intestine; hence prolonged use should be discouraged. It may be that it was induced by laxatives that are no longer in use. 130 Anthranoid-containing laxatives—aloe, cascara, frangula, and rheum—may play a role in colorectal carcinoma. Clinical epidemiologic studies have evaluated the carcinoma risk in patients who have abused anthranoid laxatives over a long period. Pseudomelanosis coli is a reliable parameter of chronic laxative abuse (more than 9–12 months) and is specific for anthranoid drugs. In a retrospective study of 3,049 patients who underwent diagnostic colorectal endoscopy, the incidence of pseudomelanosis coli was 3.13% in patients without pathologic changes. 131 In those with colorectal adenomas, the incidence increased to 8.64%, and in those with colorectal carcinoma, it was 3.29%. In a prospective study of 1,095 patients, the incidence of pseudomelanosis coli was 6.9% for patients with no abnormality seen on endoscopy, 9.8% for patients with adenomas, and 18.6% for patients with colorectal carcinomas. From these data, a relative risk of 3.04 can be calculated for colorectal carcinoma, as a result of anthranoid laxative abuse.



Mechanical Cleansers

Laxatives in this group increase propulsive activity by either increasing the bulk of the stool or changing the consistency of the stool. Traditional teaching dictates that hypertonic salts attract and retain a large volume of isotonic fluid in the gastrointestinal tract, thus stimulating peristalsis in the small intestine, reducing transit time, and causing the passage of a watery stool. Saline cathartics stimulate the release of cholecystokinin, stimulating small bowel motility, and inhibiting absorption of fluid and electrolytes from the jejunum and ileum. 132 These laxatives should be given with adequate amounts of water for two reasons: (1) the holdover in the stomach is shortened and (2) the patient suffers less dehydration. With oral administration, laxation occurs in 3 to 6 hours.


The laxative effect of bulk-forming agents is due to the absorption and retention of large amounts of water. Mechanical distention caused by this increased residue of unabsorbed material promotes peristalsis and facilitates the passage of stool. The laxative effect usually occurs within 24 hours of ingestion but may take up to 3 days. Side effects are relatively rare. Minor adverse effects include frequent flatulence and borborygmi. Esophageal, gastric, small intestinal, and colonic obstructions and fecal impactions have been reported with their use. Therefore, this group of agents should be taken with generous amounts of fluids to avoid such problems.


Liquid petrolatum retards the absorption of water from the stool and thus softens fecal material. The onset of action is approximately 6 to 8 hours. This substance can be administered orally or as an enema. The usual dose is 15 to 45 mL. Mineral oil should not be taken at bedtime because of the dangers of aspiration and is best taken between meals to obviate any tendency for interference with absorption of fat-soluble vitamins. A patient with dysphagia should not take it because of the threat of lipoid pneumonia. Pruritus ani and anal leakage are minor annoying side effects.


With its sodium or calcium salt, dioctyl sulfosuccinate lowers surface tension at the oil–water interface of the stool, thereby softening the stool by permitting a greater penetration of feces by water and fat. It has been suggested that dioctyl sulfosuccinate stimulates fluid and electrolyte secretion as well. 133 The calcium salt has been reported as more effective than the sodium salt. 134 The usual daily dose is 100 to 200 mg. They act within 24 to 48 hours.


Lactulose is a synthetic disaccharide not digested by small intestinal or pancreatic enzymes. In the colon, it is metabolized by microflora with resultant acidification of the stool and release of gas. It is effective in treating constipation and changes the nature of the colonic flora. The resultant anions may cause osmotic catharsis; for this reason, the agent might be classified with the saline laxatives. However, it is too costly for routine administration, and with long-term use, superinfection is a risk.


Several potential adverse effects may result from overconsumption of laxatives. In fact, the ill effects of laxative abuse may be greater than those of constipation. Such effects include (1) dehydration and electrolyte disturbance; (2) hypokalemia; (3) hypermagnesemia; (4) nausea, vomiting, and abdominal distress; (5) malabsorption; (6) paraffinomas; (7) lipoid pneumonia; (8) intestinal obstruction; (9) specific toxic effect; (10) anal stenosis; (11) dependence; and (12) colonic structural injury. Colonic nerve plexus damage attributed to the long-term use of sennosides has been questioned, and experimental evidence does not support this hypothesis. 130 The morphologic changes noted may very well be on an entirely different basis.



Other Pharmacologic Agents

The use of agents that enhance the normal propulsive action of the bowel is more appealing than the use of agents whose mechanism of action is by irritation. A number of agents that fall into this category are summarized in ▶ Table 33.8. Johanson et al 135 evaluated the efficacy, safety, and tolerability of tegaserod (Zelnorm, Novartis), a serotonin subtype 4 receptor, partial agonist in patients with chronic constipation in a randomized double blind, placebo-controlled study. Responder rates for complete spontaneous bowel movements (CSBMs) during weeks 1 to 4 were significantly greater in the tegaserod 2 mg twice daily (41.4%) and 6 mg twice daily groups (43.2%) versus placebo (25.1%). This effect was maintained over 12 weeks. No rebound effect was observed after treatment withdrawal. Tegaserod was well tolerated; headache and nasopharyngitis, the most frequent adverse events, were more common in the placebo group than in either tegaserod group. Kamm et al 136 also investigated the efficacy, safety, and tolerability of tegaserod in the treatment of chronic constipation. They randomized 1,264 patients to tegaserod or placebo. Responder rates for the primary efficacy variable were 35.6% for tegaserod 2 mg twice daily, 40.2% for 6 mg twice daily, and 26.7% for placebo. Tegaserod 6 mg twice daily reduced straining, abdominal bloating/distension, and abdominal pain/discomfort during the 12-week treatment period compared with placebo. Significant improvements were also seen in stool form and in global assessment of bowel habits and constipation. The most common adverse events, headache and abdominal pain, were more frequent with placebo than with tegaserod. In 2007, the FDA withdrew approval due to significantly increased risk of serious cardiovascular events compared with placebo (0.1 vs. 0.01%). A highly selective 5HT4 receptor agonist—prucalopride (Resolor)—has a much safer cardiovascular side effect profile and in 2010 was recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of constipation in women. Three randomized control trials have looked at the efficacy of prucalopride in chronic constipation. 137 , 138 , 139 The major inclusion criterion was the presence of chronic constipation, defined as two or fewer spontaneous complete bowel movements (SCBMs) per week for at least 6 months prior to screening plus any one of the following: hard/very hard stools, a sensation of incomplete evacuation, or straining, during defecation in relation to at least 25% of bowel movements. After a 2-week baseline period, eligible patients were randomized to either placebo or 2 or 4 mg of prucalopride for 12 weeks. The primary endpoint, in each study, was the proportion of patients passing at least three SCBMs per week during the 12 weeks of the trial, based on an intention-to-treat analysis. All three trials (which assessed 620, 641, and 713 patients, respectively) demonstrated a significant increase in the proportion of patients achieving at least three SCBMs per week compared with placebo. Response rates ranged from 19.5 to 31% with 2 mg prucalopride, 24 to 28% with 4 mg prucalopride, and 9.6 to 12% with placebo. Clinically relevant and statistically significant improvements were also demonstrated in a number of secondary endpoints, including satisfaction with bowel function, perception of constipation severity, and patient-assessed symptom scores. Even though men and women were enrolled in these studies, over 85% of evaluated patients were female. While this led to the approval of the drug being restricted to women, it needs to be stressed that this should not be taken to imply prucalopride is not effective in men but, rather, that it has not been adequately tested in this gender.











































Table 33.8 Agents affecting neurotransmission

General class


Mechanisms of action


Subclass


Example


Cholinomimetics


Stimulate


cholinergic receptors, predominantly muscarinics


Cholinergic agents


Bethanechol




Cholinesterase inhibitors


Neostigmine


Prokinetic agents


Facilitate release of acetylcholine and antagonize dopamine receptors



Metoclopramide



Facilitate only neurotransmitter



Cisapride


Opioid antagonists


Selectively inhibit peripheral opioid receptors



Naloxone


Source: Modified from Ogorek and Reynolds. 140


In 2014, NICE also approved the use of lubiprostone for chronic constipation. Lubiprostone is a bicyclic fatty acid derived from prostaglandin E1 that acts by specifically activating ClC-2 chloride channels on the apical aspect of gastrointestinal epithelial cells, producing a chloride-rich fluid secretion. These secretions soften the stool, increase motility, and promote spontaneous bowel movements. Several studies have established the role of lubiprostone in chronic constipation. A double-blind, placebo-controlled, dose-finding study of lubiprostone randomized 129 patients who met Rome II criteria for chronic constipation to lubiprostone at doses of 12, 24, or 36 µg twice daily or placebo for 3 weeks and recorded the frequency of spontaneous bowel movements, use of rescue medications, symptoms, and adverse events. The primary endpoint was the average daily number of bowel movements. Lubiprostone improved spontaneous bowel movement frequency in a dose-dependent manner and the overall number of bowel movements for all three doses of lubiprostone was greater than placebo at week 2. There was no statistically significant difference between the groups in serious and minor adverse events. 141 Based on the results of this study, it was determined that the lubiprostone dose of 24 µg twice daily had the best risk–benefit profile and it was chosen for subsequent phase III studies.


Additional randomized controlled trials with similar study designs have shown a significantly higher percentage of patients treated with lubiprostone had a spontaneous bowel movement within 24 hours compared with placebo (56.7 vs. 36.9%, 62.9 vs. 31.9%). There were also significant improvements in straining effort, stool consistency, and global satisfaction with bowel function compared with placebo.


Linaclotide is another drug that has had recent approval in the United States and United Kingdom. Linaclotide is a 14-amino acid synthetic peptide that is structurally related to the endogenous guanylin peptide family. It binds to and activates the guanylate cyclase C receptor on the luminal surface of the intestinal epithelium. Activation of guanylate cyclase C results in the generation of cyclic guanosine monophosphate (cGMP), the levels of which increase both extracellularly and intracellularly. Within the intestinal epithelial cells, the increase in cGMP triggers a signal-transduction cascade that activates the cystic fibrosis transmembrane conductance regulator. 142 , 143 This activation causes secretion of chloride and bicarbonate into the intestinal lumen, increasing luminal fluid secretion and accelerating intestinal transit. 144 In animal models, linaclotide has been shown to increase gastrointestinal transit and to reduce visceral pain. 145 , 146 Two randomized control trials looked at the efficacy of linaclotide in chronic constipation. 147 Patients received either placebo or linaclotide, 145 or 290 µg, once daily for 12 weeks. The primary efficacy end point was three or more CSBMs per week and an increase of one or more CSBMs from baseline during at least 9 of the 12 weeks. In the two trials, the primary end point was reached by 21.2 and 16.0% of the patients who received 145 µg of linaclotide and by 19.4 and 21.3% of the patients who received 290 µg of linaclotide, as compared with 3.3 and 6.0% of those who received placebo (p < 0.01 for all comparisons of linaclotide with placebo). Improvements in all secondary end points were significantly greater in both linaclotide groups than in the placebo groups. Its effects on abdominal pain make it a particularly attractive option in IBS-C.

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

May 17, 2020 | Posted by in GASTROENTEROLOGY | Comments Off on 33 Constipation

Full access? Get Clinical Tree

Get Clinical Tree app for offline access